MedCity News

SEPTEMBER 29, 2023

Preliminary weight loss and safety data for Structure Therapeutics’ drug candidate suggest it’s competitive with other oral GLP-1 targeting contenders from big pharma companies.

Competition 107

Competition Safety Pharma Biopharma 107

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. This allows for a complementary portfolio fit without the kind of competitive overlap that comes under regulatory scrutiny from the FTC.

Biopharma 111

Biopharma Pharma Marketing Management 111

Clarivate

OCTOBER 25, 2021

The move further expands and integrates drug toxicity data and translational safety intelligence from OFF-X into all aspects of the life science cycle. OFF-X is already integrated with several Cortellis products, including Cortellis Drug Discovery Intelligence and Cortellis Competitive Intelligence.

Safety 110

Safety Biopharma Competition Management 110

European Pharmaceutical Review

DECEMBER 19, 2022

3 Under this pathway, comparability studies are required to substantiate the similar nature, in terms of safety and efficacy, of the biosimilar and the reference product. For this reason, a unique ‘abridged’ procedure was introduced to provide a specific regulatory pathway for biosimilars in the EU.

Medicine 52

Medicine Biopharma Safety Food 52

Clarivate

JULY 31, 2023

The migration of these products and services into the Clarivate portfolio further bolster solutions that support pharmacovigilance medical literature monitoring, patent research, systematic review literature searches, MDR literature review searches, as well as competitive and business intelligence research.

Healthcare 52

Healthcare Healthcare Safety Competition 52

Clarivate

OCTOBER 25, 2023

exclusions exist for orphan drug designation and biosimilar competition ). Expect some provider practices to research using alternative treatments not subject to price negotiations for their new patients, assuming comparable efficacy, safety, and tolerability (e.g.,

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52

Marketing Safety Patients Competition 52